Jevtana
(Cabazitaxel)ApprovedSmall molecule
SanofiCabazitaxel is used to treat advanced prostate cancer in men who have already been treated with certain other chemotherapy drugs. It works by stopping cancer cells from dividing and growing.[2] Jevtana is currently approved and in use across 25 indications[4].[1]
Jevtana is one of 371 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Approved.
25
Indications
97
Total Trials
21
Active Trials
370
Competitors
3
FDA Applications
NDA/BLA/ANDA regulatory filings
10
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 25 indications
Competition
Competitive Landscape
449 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Jevtana
SanofiApproved
Yervoy
Bristol-Myers SquibbPhase 3
Rozlytrek
RochePhase 3
ONO-4538
Ono Pharmaceutical Co. LtdPhase 3
Remeron
OOrganon and Co
Preclinical
Valemetostat Tosylate
Daiichi SankyoPreclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prostate Cancer37 trials
Show 34 more trials
Cabazitaxel and Radiation For Patients With Prostate Cancer
Terminated·—·Phase 2·NCT01650285·5 enrolled
Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer
Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 1·NCT01420250·20 enrolled
Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer
Withdrawn·—·Phase 2·NCT01750866
Phase II Study of the Use of Neoadjuvant Cabazitaxel With Hormonal Treatment in Patients Operable Prostate Cancer, Assess the Efficacy and Toxicity of Cabazitaxel, and Explore Potential Predictive and Prognostic Markers of Clinical Outcome
Not yet recruiting·TThe Clatterbridge Cancer Centre NHS Foundation Trust·Phase 2·NCT04622761·120 enrolled
Metastatic Prostate Cancer5 trials
Show 2 more trials
A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer
Active, not recruiting·—·Phase 2·NCT04709276·41 enrolled
Breast Cancer3 trials
Patients With Advanced Solid Tumors3 trials
Transitional Cell Carcinoma3 trials
39 more indications
Gastric Cancer2 trials
Treatment2 trials
Urothelial Carcinoma2 trials
Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder
Active, not recruiting·—·Phase 1/2·NCT02202772·51 enrolled
Ovarian Cancer2 trials
Castration-Resistant Prostate Carcinoma2 trials
Castration Levels of Testosterone2 trials
Metastatic Castration-Resistant Prostate Cancer2 trials
Locally Advanced1 trial
A Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis
Completed·UUniversity Hospitals Bristol and Weston NHS Foundation Trust·Phase 2·NCT03114254·17 enrolled
Metastatic Colorectal Cancer1 trial
Small Cell Lung Cancer1 trial
Squamous Cell Carcinoma1 trial
Glioblastoma Multiforme1 trial
Liposarcoma1 trial
Ph II Cabazitaxel DD Liposarcoma
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT01913652·42 enrolled
Advanced Solid Cancer1 trial
Renal Impairment1 trial
Central Nervous System Tumor1 trial
Esophageal Adenocarcinoma1 trial
Carboplatin1 trial
CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone
Active, not recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT03934840·22 enrolled
Elderly1 trial
Trial1 trial
Circulating Tumor Cells1 trial
Radiotherapy1 trial
Durvalumab1 trial
Seminoma1 trial
Chemotherapy1 trial
Cabazitaxel Activity in Patients With Advanced AdrenoCortical-Carcinoma Progressing After Previous Chemotherapy Lines
Unknown status·AAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia·Phase 2·NCT03257891·25 enrolled
Solid Tumor1 trial
Lung Cancer1 trial
Prostatic Neoplasms, Castration-Resistant1 trial
Aggressive Variant Prostate Carcinoma1 trial
Metastatic Castration-resistant Prostate Neoplasms1 trial
HER2-negative Breast Cancer1 trial
Unspecified1 trial
Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin
Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT03043989·4 enrolled
Regulatory
FDA Approval Timeline[5]
Jun 17, 2010
JEVTANA KIT
NDA NDA201023
Dec 29, 2021
CABAZITAXEL
NDA NDA207949
Mar 14, 2024
CABAZITAXEL
NDA NDA207970
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Jevtana drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Cabazitaxel. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Patent Landscape[6]
Patent Cliff
Oct 27, 2030
Earliest patent expiration — generic entry possible after this date
Patent #Expires
7241907Dec 10, 2025
7241907*PEDJun 10, 2026
10716777Oct 27, 2030
8927592Oct 27, 2030
12453712Oct 27, 2030
5 more patents
10583110Oct 27, 2030
12453712*PEDApr 27, 2031
8927592*PEDApr 27, 2031
10583110*PEDApr 27, 2031
10716777*PEDApr 27, 2031